Financials data is unavailable for this security.
View more
Year on year Novoprotein Scientific Inc 's revenues fell -42.09% from 264.55m to 153.19m. This along with an increase in the cost of goods sold expense has contributed to a reduction in net income from 90.72m to 12.84m, a -85.84% decrease.
| Gross margin | 61.17% |
|---|---|
| Net profit margin | -15.82% |
| Operating margin | -24.18% |
| Return on assets | -0.94% |
|---|---|
| Return on equity | -0.99% |
| Return on investment | -0.96% |
More ▼
Cash flow in CNYView more
In 2023, cash reserves at Novoprotein Scientific Inc fell by 65.65m. However, the company earned 69.16m from its operations for a Cash Flow Margin of 45.15%. In addition the company used 81.42m on investing activities and also paid 53.93m in financing cash flows.
| Cash flow per share | -- |
|---|---|
| Price/Cash flow per share | -- |
| Book value per share | 30.57 |
|---|---|
| Tangible book value per share | 30.31 |
More ▼
Balance sheet in CNYView more
| Current ratio | 36.07 |
|---|---|
| Quick ratio | 34.60 |
| Total debt/total equity | 0.0334 |
|---|---|
| Total debt/total capital | 0.0323 |
More ▼
